2009
DOI: 10.1002/ajh.21489
|View full text |Cite
|
Sign up to set email alerts
|

A 51‐year‐old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment

Abstract: A 51-year-old male was diagnosed with chronic phase chronic myeloid leukemia (CML) in May 2005. His Sokal score at diagnosis was 0.95 and his Euro score was 1,363 (both intermediate risk). Cytogenetic examination showed 46XY, t(9;22)(q34;q11.2) in all of 30 metaphases. BCR-ABL PCR was positive for an e14a2 transcript. He was included in the HOVON-51 study (www.hovon.nl) and received two cycles of cytarabine 200 mg/m 2 for 7 days and imatinib 800 mg, q.d., continuously. Swiftly, he attained a complete and durab… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
8
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(9 citation statements)
references
References 26 publications
1
8
0
Order By: Relevance
“…Based on the finding that all self-reported hearing loss had tinnitus and subjects with self-reported hearing loss in this study had more severe degree of impairment, it is possible that tinnitus may be the actual pointer to the worsening of hearing in CML patients. This finding is consistent with what is reported in literature [5,[9][10][11][12].…”
Section: Discussionsupporting
confidence: 94%
See 1 more Smart Citation
“…Based on the finding that all self-reported hearing loss had tinnitus and subjects with self-reported hearing loss in this study had more severe degree of impairment, it is possible that tinnitus may be the actual pointer to the worsening of hearing in CML patients. This finding is consistent with what is reported in literature [5,[9][10][11][12].…”
Section: Discussionsupporting
confidence: 94%
“…It can be a presenting complaint or develop during the course of the disease. The mode of onset is usually sudden but may be gradual [5,[9][10][11][12][13][14]. Hearing impairment as initial manifestation of CML has been reported in the literature [12,13,15,16].…”
Section: Discussionmentioning
confidence: 99%
“…It is also possible that the exact incidence is under-reported based on comorbid conditions of the patient or gradual use in previous studies might have only captured Grade III and IV. Because mutations in c-Kit constitute the intended molecular target for imatinib in the treatment of GIST, it is possible that the pharmacologic inhibition of c-Kit might negatively affect hearing, probably a neurotoxic effect on the auditory nerve [7-10]. Future studies of the effect of imatinib and/or TK inhibition on the inner ear as a possible cause of imatinib-related ototoxicity are indicated.…”
Section: Discussionmentioning
confidence: 99%
“…Because these two chemotherapy drugs are used sequentially or combined with other chemotherapy drugs, clinical studies have not been planned. In the literature, erlotinib and imatinib dependent ototoxicity have been reported, as they are tyrosine kinase inhibitors that effect ototoxicity along a different pathway [1,6,9] . When we examine the studies relating tyrosine kinase inhibitors to hearing loss, many of them displayed mechanisms related to EGFR and HER [10,11] .…”
Section: Discussionmentioning
confidence: 99%
“…Also, EGFR has been found to be important in cell growth of the cochlea in rats [11] . Bilateral sensorineural hearing loss due to imatinib has been reported [9] . After daily oral usage of 400 mg imatinib, hearing loss developed on the 8 th day.…”
Section: Discussionmentioning
confidence: 99%